TY - JOUR
T1 - Is early-stage pancreatic adenocarcinoma truly early
T2 - stage migration on final pathology with surgery-first versus neoadjuvant therapy sequencing
AU - Lee, Andrew J.
AU - Simoneau, Eve
AU - Chiang, Yi Ju
AU - Lee, Jeffrey E.
AU - Kim, Michael P.
AU - Aloia, Thomas A.
AU - Vauthey, Jean Nicolas
AU - Katz, Matthew H.
AU - Tzeng, Ching Wei D.
N1 - Publisher Copyright:
© 2019 International Hepato-Pancreato-Biliary Association Inc.
PY - 2019/9
Y1 - 2019/9
N2 - Background: Neoadjuvant therapy (NT) remains controversial in early-stage pancreatic ductal adenocarcinoma (PDAC), defined as clinical (c)Stage I-II. Our aim was to analyze rates of pathologic upstaging/downstaging for resectable PDAC treated with surgery-first (SF) vs. NT. Methods: Utilizing the National Cancer Data Base (NCDB), patients with cStage I-II PDAC who underwent pancreatoduodenectomy in 2006–2013 were pathologically staged using the AJCC 8th edition and compared by treatment sequencing. Results: Among 13,871 patients, 15.3% received NT. Despite higher pre-treatment T-stage (cT2: 71.9% vs. 56.3%, p < 0.001), NT patients had lower rates of pathologic nodal metastases (46.2% vs. 69.2% in SF, p < 0.001), suggesting higher rates of pathologic downstaging. In cStage II, 33.0% were upstaged to stage III after SF, vs. only 14.0% after NT. In cStage I, 65.5% were upstaged following SF, vs. 46.7% after NT (all p < 0.001). Patients with NT (HR-0.77, p < 0.001) or downstaging (HR-0.80, p < 0.001) had improved overall survival (OS). Conclusion: NT is associated with reduction in unexpected upstaging, reduction in nodal positivity, and improved OS, compared to SF approach in putatively early-stage PDAC. Because clinical staging underestimates the underlying disease burden in resectable PDAC, patients with cStage I-II should be considered for NT.
AB - Background: Neoadjuvant therapy (NT) remains controversial in early-stage pancreatic ductal adenocarcinoma (PDAC), defined as clinical (c)Stage I-II. Our aim was to analyze rates of pathologic upstaging/downstaging for resectable PDAC treated with surgery-first (SF) vs. NT. Methods: Utilizing the National Cancer Data Base (NCDB), patients with cStage I-II PDAC who underwent pancreatoduodenectomy in 2006–2013 were pathologically staged using the AJCC 8th edition and compared by treatment sequencing. Results: Among 13,871 patients, 15.3% received NT. Despite higher pre-treatment T-stage (cT2: 71.9% vs. 56.3%, p < 0.001), NT patients had lower rates of pathologic nodal metastases (46.2% vs. 69.2% in SF, p < 0.001), suggesting higher rates of pathologic downstaging. In cStage II, 33.0% were upstaged to stage III after SF, vs. only 14.0% after NT. In cStage I, 65.5% were upstaged following SF, vs. 46.7% after NT (all p < 0.001). Patients with NT (HR-0.77, p < 0.001) or downstaging (HR-0.80, p < 0.001) had improved overall survival (OS). Conclusion: NT is associated with reduction in unexpected upstaging, reduction in nodal positivity, and improved OS, compared to SF approach in putatively early-stage PDAC. Because clinical staging underestimates the underlying disease burden in resectable PDAC, patients with cStage I-II should be considered for NT.
UR - http://www.scopus.com/inward/record.url?scp=85061842053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061842053&partnerID=8YFLogxK
U2 - 10.1016/j.hpb.2019.01.011
DO - 10.1016/j.hpb.2019.01.011
M3 - Article
C2 - 30799277
AN - SCOPUS:85061842053
SN - 1365-182X
VL - 21
SP - 1203
EP - 1210
JO - HPB
JF - HPB
IS - 9
ER -